A presença de invasão vascular no enxerto apresentou impacto na recidiva. Não houve diferenças significativas nas taxas de recidiva e sobrevida quando comparamos THDV e THDC.
Nenhum dos fatores prognósticos estudados influenciou a mortalidade por CHC no período pós transplante hepático.
O MELD score não modificou a sobrevida pós-transplante a longo prazo no grupo THDC em nosso centro.
8 REFERÊNCIAS BIBLIOGRÁFICAS
1 - Vakili K, Pomposelli JJ, Cheah YL, Akoad M et al. Living donor liver
transplantation for Hepatocellular carcinoma: increased recurrence but improved survival. Liver Transplantation 2009; 15:1861-1866.
2 - Silva M. O impacto do MELD para o carcinoma hepatocelular na realidade do Brasil. Gastroenterologia Endoscopia Digestiva, GED . 2011: 3:10-72.
3- Sandhu L, Sandroussi C, Guba M, Selzner M et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular
carcinoma: comparable survival and recurrence. Liver Transplantation 2012; 18: 315- 322.
4-Revista Brasileira de Transplantes . Associação Brasileira Transplante de Orgãos, ABTO. Disponível em : http://www.abto.com.br/rbt/registros/ acessada em 2009.
5- Pinto, F. Mortalidade por neoplasias no Brasil (1980/1983/1985): agrupamento dos Estados, comportamento e tendências. Revista de Saúde Pública1991, 25(4): 76-281.
6-INCA/MS. Instituto Nacional do Câncer/Ministério da Saúde. Estimativas da incidência e mortalidade por câncer no Brasil. Rio de Janeiro: Gráfica do Pro- OncoINCA/MS, 2002.
7- World Health Organization. Mortality data.
http://www.who.int/healthinfo/statistics/mortality/en/index.html. Acessado em 2011
8- Boschi C, Coleman MP, Castilho EA. Diferenciais regionais de mortalidade por câncer no Estado do Rio de Janeiro, Brasil, 1979-1981. Revista de Saúde Pública. 1991; 25(4): 267-275.
9- Gomma A, Khan M, Toledano M, Waked I, Taylor-Robison S. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. Word J Gastroenterol 2008; 14(27): 4300-08.
10- Parolin M, Coelho J, Matias J, Bareta G. Resultados do transplante Hepático com o diagnóstico pré operatório de carcinoma hepatocelular. Arq Gastroenterol 2006; 43(4):259-64.
11- Lo CM, Fan CL, Chan SC. Living donor versus deceased donor liver
transplantation for early irresectable hepatocellular carcinoma. Bristish Journal of Surgery 2007; 94:78-86
12- Khoshayar V, Pomposelle J, Cheah YL . Living donor liver transplantation for hepatocellular carcinoma: increased recurrence but improved survival. Liver Transplantation. 2009; 15: 1861-1866.
13- Fisher R A, Kulikb L M, Freisec C E. A2ALL Study Group . Hepatocellular Carcinoma Recurrence and Death Following Living and Deceased Donor Liver Transplantation. American Journal of Transplantation 2007; 7: 1601–1608.
14- Dias MB. Carcinoma Hepatocecular , história natural, sobrevida e amostra hospitalar no Rio de Janeiro. Dissetação de Mestrado pela Fundação Oswaldo Cruz,2003.
15- Mc Glynn K, London WT. Epidemiology and Natural history of hepatocellular carcinoma. Best Practice and Research Gastroenterology,2005:19:1-22.
16- Hussain SP, Harris C C, Molecular epidemiology and carcinogenesis:
endogenous and exogenous carcinogens. Mutation Research. 2000; 462: 311-322. 17- Oliveira ES A, D’albuquerque L A C, Chaib E, Saad W A, Pinotti H W. 1995. Pequeno carcinoma hepatocelular. Arquivos de Gastroenterologia. 32(1): 15-18.
18- Bruix J, Sherman M, Llovet J, Beaugrand M, Lencioni R, Burroughs A, Christensen E, Pagliaro l, Colombo M. Clinical Management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. Journal of Hepatology. 2001; 35: 421-430.
19-Bruix J, Sherman M. American Association for the Study of Liver Diseases , Management of hepatocellular carcinoma. Hepatology, 2005; 42(5):1208-1228. 20- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. European Association, Journal of Hepatology 2012;56: 908-943.
21- Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. Journal Clinical Oncology 2002; 20:1527.
22- Vauthey JN, Ribero D, Abdalla EK, et al. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. Journal American College Surgical 2007; 204:1016.
23- Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56:918.
24- Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP). Hepatology 2000; 31:840.
25-Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002; 50:881.
26- Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41:707. 27- Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with
hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89:2266.
28- Bruix J, Sherman M. Management of Hepatocellular Carcinoma . AASLD, Practice Guideline. Hepatology ,2011; 53(3): 1020-1058.
29- Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzeti F, Montolto F, Annaturoni M, Moobito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of
Medicine. 1996;334:693.
30- Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
31- Vauthey JN, Lauwers GY, Esnaola NF, Do KA, BelghitiJ, et al. . Simplified staging for hepatocelular carcinoma. Journal Clinic Oncology 2002;20:1527-1541. 32- Sharma P, Balan V, Hernandez JL, Harper AM, et al. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transplantation 2004;10:36-41 33- http://dtr2001.saude.gov.br/sas/PORTARIAS .Portaria do Ministério da Saúde regulamentando e implantando o MELD < acessado em 2011>
34- Hwang LH. Gene therapy strategies for hepatocellular carcinoma. J Biomed Sci 2006;13(4): 453–68.
35- Hernandez-Alcoceba R, Sangro B, Prieto J. Gene therapy of liver cancer. World Journal of Gastroenterology 2006;12(38):6085–97.
36- Llovet JM, Wurmbach E. Gene expression profiles in hepatocellular carcinoma: notyet there. Journal of Hepatology . 2004;41:336-9.
37- Caturelli E, Bartolucci F, Biasini E, Vigliotti ML, Andriulli A, Siena DA, Antino V , Bisceglia M, 2002. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. American Journal of Gastroenterology, 97(2): 397-405.
38- Figueras J, Jaurrieta E, Valls C, Benasco C, Rafecas A, Xiol X, Fabregat J, Casanovas T ,Torras J, Baliellas C, Ibanez L, Moreno P, Casais L. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology. 1997;25:1485-9.
39-Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Denison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Annals Surgic. 1993;218:145-5.
40- Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, Rosen M, Soulen M, Shaked A, Reddy KR, Olthoff KM. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver
Transplantation. 2004;10:911-8.
41- Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR,Schwartz ME. Recurrence of hepatocellular carcinoma after liver transplant: patternsand prognosis. Liver Transplantation. 2004;10:534-40.
42- Ludwig Wilkens. Induction of aneuploidy by increasing chromosomal instability during dedifferentiation of hepatocellular carcinoma, PNAS 2004 ;(101): 1309-14. 43- Hoshida Y et al. Gene Expression in Tissues and Outcome in Hepatocellular Carcinoma, New Egland Journal of Medicine 2008; 359(19): 1995-04.
44- Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 -cases among 48,900 necropsies. Cancer. 1954;7:462-503.
45- Tsoulfas G, Kawait T, Elias N, et al. Long-term experience with liver
transplantation for carcinoma hepatocelular. Journal of Gastroenterology, 2011;46: 249-256.
46- Gouw AS, Balabaud C,Kusano H, et al. Markers for Microvascular Invasion in
Hepatocellular Carcinoma: Where Do We Stand? Liver Transplantation.
2011;17:S72-80.
47- Schaubel DE, Guidenger M K, Biggens SW, et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant. 2009; 9 : 970-981.
48- Merion RM, Schaubel DE, Dykstra DM. The survival benefit of liver transplantation. Am J Transplant. 2005;5:307-313.